Novartis
NVS
1,090 hedge funds and large institutions have $21.2B invested in Novartis in 2019 Q3 according to their latest regulatory filings, with 71 funds opening new positions, 356 increasing their positions, 446 reducing their positions, and 69 closing their positions.
5% more call options, than puts
Call options by funds: $162M | Put options by funds: $154M
3% more first-time investments, than exits
New positions opened: 71 | Existing positions closed: 69
0% less funds holding
Funds holding: 1,094 → 1,090 (-4)
0.51% less ownership
Funds ownership: 10.08% → 9.57% (-0.51%)
10% less capital invested
Capital invested by funds: $23.5B → $21.2B (-$2.26B)
20% less repeat investments, than reductions
Existing positions increased: 356 | Existing positions reduced: 446
52% less funds holding in top 10
Funds holding in top 10: 29 → 14 (-15)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$102M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
+$71.2M |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$61.9M |
| 4 |
SC
Sculptor Capital
New York
|
+$29.4M |
| 5 |
Jennison Associates
New York
|
+$29.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$258M |
| 2 |
Dodge & Cox
San Francisco,
California
|
-$238M |
| 3 |
Boston Partners
Boston,
Massachusetts
|
-$181M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$141M |
| 5 |
BBHC
Brown Brothers Harriman & Co
New York
|
-$108M |
NVS Hedge Fund Activity: Q3 2019 in Review
1,090 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Novartis (NVS) for Q3 2019, worth a combined $21.2B — down 9.6% from $23.5B a quarter earlier.
Buyers outnumbered sellers: 71 funds opened new NVS positions and 69 closed out — a net gain of 2 holders — while 356 added to existing stakes and 446 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $102M. The largest seller was BlackRock, cutting an estimated $258M.
- 1,090 institutional investors held Novartis (NVS) as of Q3 2019, down from 1,094 in Q2 2019.
- Funds reported $21.2B of Novartis stock for Q3 2019, down 9.6% quarter-over-quarter.
- 71 funds opened new Novartis positions in Q3 2019 and 69 closed out, a net change of +2 holders.
- The largest Novartis buyer in Q3 2019 was Renaissance Technologies, an estimated $102M added.
- The largest Novartis seller in Q3 2019 was BlackRock, an estimated $258M sold.
Based on aggregated 13F filings for Q3 2019.